Alerta

Compositions, Kits, and Methods Comprising Bioidentical D BHB With Optional Vitamin B6 for Neurological Wellness, Mood Stability, and Medication Taper Support

Absstract of: US20260306430A1

Compositions, kits, and methods are disclosed for nutritional neurometabolic support and improved gut health using bioidentical D-beta-hydroxybutyric acid (D-BHB) to promote neurological wellness, mood stability and adaptive brain function during everyday life and during changes in neurologically acting medication regimens. The compositions comprise a salt-free, ester-free, alcohol-free D-BHB acid formulation optionally configured with vitamin B to raise circulating ketone levels, supply a preferred brain energy substrate, and support intestinal barrier integrity by improving tight junction function and reducing paracellular leakiness, thereby influencing gut-brain axis signaling. The compositions optionally incorporate B vitamins with vitamin B6 being a preferred embodiment to complement bioidentical D-BHB by supporting neurotransmitter synthesis and related gut-brain pathways. Kit (701) provides unit dose containers of bioidentical D-BHB, with or without B-vitamin supplementation and optional tapered pharmaceutical doses, together with optional software or AI-based tools configured to capture diet and mood data via smartphone and to generate guidance for nutritional and medication-taper support.

METHODS AND COMPOSITIONS FOR DIAGNOSING BRAIN INJURY OR NEURODEGENERATION

Absstract of: US20260309724A1

Methods and compositions for diagnosing brain injury, neurodegeneration; or a predisposition thereto, in a subject are provided. Particularly, the present invention relates to specific antigen antibody reactivities useful in diagnosing brain injury, neurodegeneration or a predisposition thereto, in a subject.

Methods for Verification of Drug Levels Using Dried Blood Samples

Absstract of: US20260309705A1

Provided herein are methods for monitoring treatment for multiple sclerosis in a pregnant subject, and determining the efficacy of a treatment for multiple sclerosis in a pregnant subject. These methods include (a) extracting a drug from a dried blood spot (DBS) sample from a pregnant subject after a treatment for multiple sclerosis has been administered to the pregnant subject; (b) performing mass spectrometry on the extracted DBS sample; (c) determining a peak area ratio of the extracted DBS sample to an internal standard; and (d) identifying the administered treatment as being below the internal standard threshold if the plasma concentration of the treatment is less than 1 as compared to the internal standard ratio. Also provided herein are dried blood spot cards, and kits that include a dried blood spot card pre-treated with at least one internal standard.

NOVEL LILRB2 ANTIBODIES AND USES THEREOF

Absstract of: US20260309715A1

0000 Provided herein are antibodies binding to LILRB2 and the uses of the antibodies in detecting and treating cancer and autoimmune diseases.

METHODS, USES AND COMPOSITIONS

Absstract of: WO2026209799A1

The present application discloses a method of monitoring and/or determining the responsiveness of a subject's eye having capillary retinal perfusion dysfunction, to an administration of a first dose of Annexin A5 to the subject, wherein the method comprises assessing the health of the eye and/or assessing total plasma concentration of phosphatidylserine (PS) at about or within a week, 6 days, 5 days, 4 days, 3 days, 2 days or 1 day, of the administration of the first dose of the Annexin A5 to the subject. These methods permit the rapid stratification of subjects into appropriate treatment groups, and the early onset of a treatment regime that is therapeutically appropriate to the subject.

Ｍ２マクロファージ分化誘導促進剤

Absstract of: JP2026158933A

【課題】皮膚における血管周囲のマクロファージの性質、及び当該マクロファージが血管や皮膚性状に与える影響を明らかにし、新規作用機序に基づく有用な製剤を提供することを課題とする。【解決手段】本発明者らは、誠意研究の結果、皮膚において、毛細血管周囲にＭ２マクロファージが取り囲むように存在すること、Ｍ２マクロファージの培養上清を、血管内皮細胞に添加すると、血管安定化が促進することを発見した。そこで、Ｍ２マクロファージ分化誘導を促進する化粧料素材を探索し、アカツメクサ花エキス、モモ葉エキス、及びアセロラ種子エキスからなる群から選ばれる１又は複数のエキスを含む、Ｍ２マクロファージ分化誘導促進剤、Ｍ２マクロファージ分化誘導促進を介した血管安定化剤、Ｍ２マクロファージ分化誘導促進を介した美白剤を提供する。【選択図】図４

An ink formulation

Absstract of: GB2705330A

An ink for a screen-printed electrode comprises gold microstructures with a maximum dimension of 0.05-7.5 microns and a polymer dissolved or dispersed in one or more solvents having a boiling point of >110C. The ink may comprise 7.5-25 wt.% gold microstructures, 4-15 wt.% polymer, and 45-65 wt.% solvent. The gold microstructures may be microspheres or microflakes. The polymer may comprise polyethylene terephthalate, polyethyloxazoline, polymethylmethacrylate, polyacrylates, polyesters, polyamines, polyethers, polyvinyl acetate, polyvinyl chloride, polyhydroxyethers, cellulose derivatives, or poly(lactide). The solvent may be alpha-terpineol, di(propylene glycol) methyl ether, or propylene glycol monomethyl ether acetate. A method of making an electrode comprises screen-printing a working electrode onto a substrate using the ink and providing reference and counter electrodes on the substrate. A method of detecting a target analyte in a sample comprises contacting the electrode with the sample, wherein a response characteristic of the electrode is capable of being operably varied, thereby indicating the presence of the analyte. No Figure

サーバ装置、分析方法、及びプログラム

Absstract of: US20260224206A1

0000 An excrement analysis apparatus includes an inputter, a memory, a first analyzer, and a second analyzer. The inputter inputs imaging data captured by an image capture apparatus installed in such a way as to include, in a capturing range, an excretion range of excrement in a toilet bowl of a toilet. The memory temporarily holds the imaging data input by the inputter. The first analyzer analyzes first analysis target data being the imaging data input by the inputter, and outputs notification information to an observer who observes a user of the toilet. The second analyzer analyzes second analysis target data being the imaging data that is input by the inputter and temporarily held by the memory, and outputs detailed information indicating a content of excretion.

PREDICTION OF PREECLAMPSIA RISK USING CIRCULATING, CELL-FREE RNA

Absstract of: EP4818331A2

0001 The disclosure describes changes in cfRNA gene expression that are associated with risk for preeclampsia. Accordingly, the disclosure provides methods and kits for preeclampsia risk assessment.

PHARMACEUTICAL PREPARATION FOR DIAGNOSING AND TREATING ALZHEIMER'S DISEASE

Absstract of: EP4818330A1

The present invention relates to the field of biomedicine. Provided are a marker that can be used for early diagnosis of Alzheimer's disease, and the use thereof. Specifically provided is a marker for early diagnosis of Alzheimer's disease. The marker is a Maf1 gene or the protein rhereof. High expression of the Maf1 gene or the protein thereof in neuronal cells indicates that a subject is at high risk of developing Alzheimer's disease. The method provides a new diagnostic and therapeutic target for AD.

ＧＤＦ－１５結合核酸分子、ＧＤＦ－１５を検出するためのキット、及びＧＤＦ－１５を検出するための方法

Absstract of: JP2026156851A

【課題】 本開示は、ＧＤＦ－１５に対する優れた結合能を有する核酸分子を提供する。【解決手段】 本開示のＧＤＦ－１５結合核酸分子は、（ａ１）配列番号７の塩基配列を含み、且つ、ＧＤＦ－１５に結合するポリヌクレオチド、（ａ２）配列番号７の塩基配列において１若しくは数個の塩基が欠失、置換、挿入、及び／又は付加された塩基配列を含み、且つ、ＧＤＦ－１５に結合するポリヌクレオチド、又は（ａ３）配列番号７の塩基配列に対して８０％以上の同一性を有する塩基配列を含み、且つ、ＧＤＦ－１５に結合するポリヌクレオチドを含み、配列番号７の塩基配列において下線で示されるＴは、チミン塩基又は修飾チミン塩基である。【選択図】 図９

一种验证吴茱萸碱改善D-gal诱导衰老认知及运动功能障碍的方法

Absstract of: CN122849250A

0001 本发明公开了一种验证吴茱萸碱改善D‑gal诱导衰老认知及运动功能障碍的方法，属于医学方法验证技术领域。选择雄性小鼠，并分为对照组、D‑半乳糖模型组、DFMO干预组、吴茱萸碱干预组；进行新行为学测试后处理小鼠；分别取每组小鼠眼球血进行血清生化检测；采集组织样本，采用BCA法测定蛋白浓度后，再进行免疫组织化学与免疫荧光测试，而后再进行代谢物检测；培养、处理细胞后进行siRNA转染，进行分子对接评估吴茱萸碱与ODC1的结合能力及相互作用模式；最后分析统计结果。本发明发现吴茱萸碱可显著改善衰老小鼠认知和运动功能障碍，降低脑组织尿素水平，下调尿素循环关键酶表达，抑制P53表达。

靶向TSLP和IL-4/IL-4R的双功能融合蛋白及其应用

Absstract of: CN122872563A

0001 本公开属于生物医药领域，具体涉及靶向TSLP和IL‑4/IL‑4R的双功能融合蛋白及其应用。本公开的双功能融合蛋白对IL‑4R、IL‑4和/或TSLP具有较好的亲和力和/或生物学活性，可用于检测IL‑4R、IL‑4和/或TSLP、诊断或防治与IL‑4R、IL‑4和/或TSLP相关的疾病或病症。

Aβ1-42抗体及其制备方法和应用

Absstract of: WO2026199818A1

The present application provides a method for preparing a humanized Aβ1-42 antibody and use thereof. Specifically, the antibody of the present application combines a murine antibody variable region and a human antibody framework region; on the basis of specifically binding to an Aβ peptide segment, the antibody reduces immunogenicity due to its humanized framework region. The antibody has the advantages of high affinity, high specificity, low immunogenicity, and scalability for large-scale production. The antibody of the present application can be used for detecting an Aβ1-42 antigen, eliminating Aβ deposits, or treating related diseases thereof, such as Alzheimer's disease.

抗ＭＣＴ１抗体およびその使用

Absstract of: AU2019205489A1

This invention generally pertains to antibodies and antigen-binding fragments thereof, e.g., humanized, chimeric, and human antibodies and antigen-binding fragments thereof, and fusion proteins, compositions containing such antibodies and antigen-binding fragments thereof and fusion proteins, wherein such antibodies and antigen-binding fragments thereof and fusion proteins specifically bind to MCT1, e.g., human or non-human MCT1 and antagonize, inhibit or block one or more MCT1-associated functions

原形質膜アンカー型プロテアーゼを利用するための系および方法

Absstract of: WO2025059015A1

Described herein is a system comprising a eukaryotic cell, wherein the eukaryotic cell comprises: a plasma membrane polypeptide coupled to a transcription factor by a linker, wherein the linker comprises a protease cleavable site; and a plasma membrane anchored protease; wherein the plasma membrane anchored protease is capable of cleaving the linker. The system can further include a reporter construct, wherein the transcription factor can bind to a promoter of the reporter construct to indicate an ability of the plasma membrane polypeptide to traffic to the plasma membrane.

ANTIBODIES RECOGNIZING TAU

Absstract of: MX2026009889A

The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

抗Aβ1-40抗体及其制备方法和应用

Absstract of: WO2026199817A1

The present application provides a method for preparing a humanized Aβ1-40 antibody and use thereof. Specifically, the antibody of the present application combines a murine antibody variable region and a human antibody framework region; on the basis of specifically binding to an Aβ peptide segment, the antibody reduces immunogenicity due to its humanized framework region. The antibody has the advantages of high affinity, high specificity, low immunogenicity, and scalability for large-scale production. The antibody of the present application can be used for detecting an Aβ1-40 antigen, eliminating Aβ deposits, or treating related diseases thereof, such as Alzheimer's disease.

PROTEIN FREE SOLUTION FOR STABILIZING IMMUNOASSAY CALIBRATORS

Absstract of: US20260298949A1

0000 Disclosed and claimed are compositions containing a calibrator and a stabilizer, wherein the stabilizer includes Diethylaminoethyl-(“DEAE”) dextran; D-Sorbitol, wherein the D-Sorbitol and DEAE-dextran are in a weight ratio from about 1:1 to about 5:2, a buffer; and a non-ionic surfactant; wherein the stabilizer is essentially free of bovine serum albumin; and wherein the calibrator is stabilized under frozen storage conditions, and remains stable when thawed and kept at temperatures of from about 2° C. to about 10° C. Also disclosed are methods of use of the claimed compositions and kits comprising the claimed compositions.

NANOPARTICLE ENHANCED METHODS AND MATERIALS FOR DETECTING MISFOLDED POLYPEPTIDES

Absstract of: US20260298917A1

0000 This document relates to methods and materials for detecting the presence or absence of misfolded polypeptides in a sample. For example, a sample (e.g., a biological sample or an environmental sample) can be exposed to nanoparticles (e.g., nanoparticles having a size of no more than 2 μm (e.g., no more than 1 μm) such as silica nanoparticles (siNPs) having a size of no more than 2 μm (e.g., siNPs having a size of no more than 1 μm)) during a seeded amplification assay to accelerate the aggregation of misfolded polypeptides present in the sample into fibrils and/or polypeptide aggregates (e.g., globular polypeptide aggregates). In some cases, methods and materials provided herein can be used to determine if a mammal (e.g., a human) has a proteinopathy based, at least in part, in the presence or absence of misfolded polypeptides in a sample obtained from the mammal.

PATROLLING MONOCYTE CELLULAR THERAPY

Absstract of: US20260297525A1

Disclosed herein are methods of expanding populations of patrolling monocytes in vitro and in vivo for treatment of sickle-cell disease (SCD), reducing pain and vaso-occlusive events in SCD patients, promoting wound healing, reducing tumor metastases, and treating vascular inflammatory conditions in subjects in need thereof.

METHODS OF DETERMINING GLUCOSE HYPOMETABOLISM-INDUCED ENERGY CRISIS AND TREATMENTS THEREOF

Absstract of: WO2026207251A1

The present disclosure provides systems, methods, compositions, and algorithms for treating a subject diagnosed with a glucose hypometabolic disorder (e.g., Alzheimer's disease, Parkinson's disease, or heart failure).

METHODS OF DIAGNOSING AND TREATING NEURODEGENERATIVE DISEASE

Absstract of: WO2026206859A1

Described herein are methods and kits for the early diagnosis of neurodegenerative diseases, such as Alzheimer's disease, by detecting the enzymatic activities of L1 variants. Increased levels of the enzymatic activities serve as biological indicators that can signal the presence or risk of developing such diseases, preceding the visible or detectable changes identified by conventional techniques. Also provided herein, are methods of treating neurodegenerative diseases following early diagnosis.

PHOSPHORYLATED TAU IMMUNOASSAYS AND METHODS OF PRODUCING AND USING SAME

Absstract of: WO2026207302A1

Compositions, kits, systems, and methods for determining the presence and/or concentration of a phosphorylated Tau biomarker (such as, but not limited to, pTau217) in a biological sample and/or determining the presence of, severity of, and/or predisposition to Alzheimer's disease in an individual are disclosed. The compositions, kits, systems, and methods utilize at least two means for binding to Tau, including one means that is capable of distinguishing the phosphorylated Tau biomarker from unphosphorylated Tau, so that at least one sandwich complex can be formed. The methods include determining an amount of pTau present in the biological sample based on the amount of the sandwich immunocomplex formed.

ALPHA-SYNUCLEIN ASSAY

Nº publicación: WO2026202211A1 01/10/2026

Applicant:

NORDIC BIOSCIENCE AS [DK]
NORDIC BIOSCIENCE A/S

Absstract of: WO2026202211A1

Methods of immunoassay are described for detecting in a patient sample (such as for example a blood, serum or plasma sample) a biomarker originating from α-Synuclein, and to the use of said methods of immunoassay for detecting and/or monitoring Parkinson's Disease or a level of severity thereof. Monoclonal antibodies and assay kits for use in said methods of immunoassay are also described.